PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$26.35
−0.94%Year over year
Reported trailing growth
- Revenue
- +5.7%
- EBITDA
- +8920.6%
- EBIT
- +117.7%
- EPS
- +112.7%
- Free cash flow
- +53.3%
- Operating cash flow
- +39.5%
Forward estimates
Based on analyst estimates
- Revenue
- +1.2%
- EBITDA
- +120.1%
- EPS
- +769.1%
Three-year CAGR
- Revenue
- +2.9%
- EBITDA
- -4.4%
- EBIT
- -17.8%
- Net income
- -23.8%
- EPS
- -23.0%
- Free cash flow
- +5.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026